Overview
Chinese First Episode Schizophrenia's Optimal Dynamic Antipsychotic Treatment Regime
Status:
Unknown status
Unknown status
Trial end date:
2021-09-01
2021-09-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This project is mainly to clarify the optimal treatment plan and the treatment recommendation sequence of different drugs in Chinese first-episode schizophrenia patients,to identify the optimized sequential treatment regimen for the treatment of resistance patients and provide new evidence for the revision of the guidelines for the treatment of schizophrenia.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Shanghai Mental Health CenterTreatments:
Amisulpride
Antipsychotic Agents
Aripiprazole
Olanzapine
Paliperidone Palmitate
Risperidone
Sultopride
Criteria
Inclusion Criteria:- Meet the diagnostic criteria of Diagnostic and Statistical Manual Diploma in Social
Medicine(DSM-V) schizophrenia or schizophreniform psychosis
- Patient interview using the MINI-International Neuropsychiatric Interview(MINI 7.0)
- 18 to 40 years of age
- First episode, disease course less than 3 years
- Antipsychotic naïve, or the time of taking the same type of antipsychotic <2 weeks (2
weeks is a time criterion to determine the efficacy in lots of studies), and
cumulative antipsychotic drug exposure time <6 weeks Informed consent.
In addition, the severity of psychiatric symptoms is moderate or above, the specific
criteria are:
- All patients have a score ≥4 on at least one Positive and Negative Syndrome Scale
(PANSS; 17) psychosis item (delusions, conceptual disorganization, hallucinatory
behavior, grandiosity, or suspiciousness/persecution)
- All patients have a score ≥4 (moderately ill) on the severity item of the Clinical
Global Impression scale (CGI; 19) at the point of maximum severity of illness to date
Exclusion Criteria:
- organic disease
- severe physical illness
- psychoactive substance dependence
- mental retardation
- pregnancy or breast-feeding patients
- extreme agitation, stupor, negative suicide
- other non-cooperation or risk patients